SER-109 is an investigational microbiota-based product for fecal microbiota transplantation (FMT). It is proposed to prevent recurrent Clostridioides (formerly Clostridium) difficile infection (CDI) in adults with a history of 3 or more CDI episodes within a 9-month period. SER-109 is…
Publications
Researched and Curated by Clinical and Scientific Experts.Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.
Not all reports are available for public preview. For more information, please contact us.
RBX2660 for Fecal Microbiota Transplantation
RBX2660 is a microbiota-based investigational product for fecal microbiota transplantation proposed to treat recurrent Clostridium difficile infection. It is derived from fresh stool from multiple donors; both donors and stool samples are methodically screened. Pooled stool samples are commercially prepared under good manufacturing processes. RB…
Fintepla (Fenfluramine) for Seizures Associated with Dravet Syndrome
Fenfluramine is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of seizures associated with Dravet syndrome in patients aged 2 years and older.
Occipital Nerve Stimulation for Chronic Migraine Headache
If you have a Hayes login, click here to view the full report on the Knowledge Center.
Tisagenlecleucel (Kymriah) for Treatment of Relapsed or Refractory CD19+ B-Cell Malignancies
Focus of the Report: This report evaluates the use of tisagenlecleucel (Kymriah) for the treatment of relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) or r/r diffuse large B-cell lymphoma (DLBCL).
Technology Description: Tisagenlecleucel therapy is a form of chime…
Givlaari (Givosiran) for Acute Hepatic Porphyria
Givlaari is a subcutaneously administered ribonucleic acid interference (RNAi) agent that inhibits delta-aminolevulinate synthase 1 (ALAS1) synthesis, a key regulator of the heme biosynthetic pathway in the liver. Givlaari is believed to reduce ALAS1 levels, thereby decreasing delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Decreasing ALA and PBG levels to n…
Genicular Nerve Block for the Management of Knee Pain
Focus of the Report: This health technology assessment focuses on the use of genicular nerve blocks (GNB) for the management of knee pain associated with osteoarthritis of the knee (KOA) or persistent pain following total knee arthroplasty (TKA).
Technology Description: In a GNB proced…
Electronic Monitoring Versus Direct Observation of Hand Hygiene Compliance in Healthcare Settings
Focus of the Report: This report focuses on electronic monitoring (EM) of hand hygiene (HH) in a hospital setting.
Technology Description: Electronic HH monitoring systems vary in their degree of sophistication. The simplest are straightforward counters that record the number of times …
Lisocabtagene Maraleucel for Large B-Cell Lymphoma
Lisocabtagene maraleucel (liso-cel) is an investigational, autologous chimeric antigen receptor (CAR) T-cell therapy, a novel type of immunotherapy in which a patient’s own immune cells are genetically re-programmed to target and attack cancer cells. It is proposed to treat adults with relapsed or refractory large B-cell lymphoma after at least 2 prior therapies. This patient…
Magnetic Resonance Elastography for Detecting and Staging Liver Fibrosis
Focus of the Report: This report focuses on magnetic resonance elastography (MRE) for diagnosis and staging of liver fibrosis.
Technology Description: MRE relies on visualization of the passage of sound waves through liver tissue while the patient is in a magnetic resonance imaging (MR…